/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Our Company The Company s objective is to develop and commercialize products utilizing novel technology that enhances the delivery of drugs and other compounds to the brain and other tissues for a variety of indications. Our novel technology was originally developed by researchers in the Department of Neurosurgery at Duke University and licensed by us in 2023.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$5M
▼ -65.5% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$3M
▼ -635.9% YoY
Net Debt
-$670K
Net Cash Position
Cash & Equiv.
$670K
Continue Research
SourceComputed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.